Outcomes
newly-onset nephrolithiasis/renal cyst, gout, hemoglobinuria, MetS
ADVERSE EVENTS, ADVERSE EVENT, MSU, SKIN ALLERGY, GOUT, HYPERTENSION
The primary outcomes were changes in urine pH and sUA level over 12 weeks. Gout-related outcomes included changes of CRP level, gout flares and changes in DECT-detected monosodium urate (MSU) volume. The renal and metabolic outcomes included changes in eGFR, UACR, and MetS components (including BP, BMI, FBG, HOMA-IR, and blood lipids). Adverse events included changes in serum electrolyte level, newly-onset hemoglobinuria, newly-onset nephrolithiasis/renal cyst examined by kidney ultrasonography, newly-onset hypertension, skin allergy, transaminase elevation, and other adverse events that might lead to treatment interruption or hospitalization.